Literature DB >> 27096597

Ibrutinib for Chronic Lymphocytic Leukemia.

Rosa Ruchlemer1, Ronen Ben Ami2, Tamar Lachish3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27096597     DOI： 10.1056/NEJMc1600328

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  15 in total

1.  Antibody immunity and natural resistance to cryptococcosis.

Authors:  N Trevijano-Contador; L Pirofski
Journal:  Curr Trop Med Rep       Date:  2019-04-04

Review 2.  Current Status of Bruton's Tyrosine Kinase Inhibitor Development and Use in B-Cell Malignancies.

Authors:  Andrew Aw; Jennifer R Brown
Journal:  Drugs Aging       Date:  2017-07       Impact factor: 3.923

Review 3.  Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies.

Authors:  Joshua S Davis; David Ferreira; Emma Paige; Craig Gedye; Michael Boyle
Journal:  Clin Microbiol Rev       Date:  2020-06-10       Impact factor: 26.132

Review 4.  Cryptococcus neoformans empyema in a patient receiving ibrutinib for diffuse large B-cell lymphoma and a review of the literature.

Authors:  Christopher David Swan; Thomas Gottlieb
Journal:  BMJ Case Rep       Date:  2018-07-18

5.  Serious Infections in Patients Receiving Ibrutinib for Treatment of Lymphoid Cancer.

Authors:  Tilly Varughese; Ying Taur; Nina Cohen; M Lia Palomba; Susan K Seo; Tobias M Hohl; Gil Redelman-Sidi
Journal:  Clin Infect Dis       Date:  2018-08-16       Impact factor: 9.079

6.  Inhibition of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma.

Authors:  Michail S Lionakis; Kieron Dunleavy; Mark Roschewski; Brigitte C Widemann; John A Butman; Roland Schmitz; Yandan Yang; Diane E Cole; Christopher Melani; Christine S Higham; Jigar V Desai; Michele Ceribelli; Lu Chen; Craig J Thomas; Richard F Little; Juan Gea-Banacloche; Sucharita Bhaumik; Maryalice Stetler-Stevenson; Stefania Pittaluga; Elaine S Jaffe; John Heiss; Nicole Lucas; Seth M Steinberg; Louis M Staudt; Wyndham H Wilson
Journal:  Cancer Cell       Date:  2017-05-25       Impact factor: 31.743

Review 7.  Immunological changes with kinase inhibitor therapy for chronic lymphocytic leukemia.

Authors:  Christopher Pleyer; Adrian Wiestner; Clare Sun
Journal:  Leuk Lymphoma       Date:  2018-05-15

8.  Call for Action: Invasive Fungal Infections Associated With Ibrutinib and Other Small Molecule Kinase Inhibitors Targeting Immune Signaling Pathways.

Authors:  Georgios Chamilos; Michail S Lionakis; Dimitrios P Kontoyiannis
Journal:  Clin Infect Dis       Date:  2018-01-06       Impact factor: 9.079

9.  Disseminated Cryptococcosis With Brain Involvement in Patients With Chronic Lymphoid Malignancies on Ibrutinib.

Authors:  Julia A Messina; Eileen K Maziarz; Andrej Spec; Dimitrios P Kontoyiannis; John R Perfect
Journal:  Open Forum Infect Dis       Date:  2017-02-09       Impact factor: 3.835

10.  Invasive aspergillosis related to ibrutinib therapy for chronic lymphocytic leukemia.

Authors:  Benjamin Arthurs; Kathy Wunderle; Maylee Hsu; Suil Kim
Journal:  Respir Med Case Rep       Date:  2017-03-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.